Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer

Current Opinion in Oncology

Volumn 22, Issue 3, 2010, Pages 206-211

  Marur, Shanthi ^a   Forastiere, Arlene A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antiepidermal growth factor receptor; Chemoradiation; Epidermal growth factor receptor; Head and neck squamous cell cancer; Intensity modulated radiation therapy; Vascular endothelial growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; RADIOSENSITIZING AGENT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT REFUSAL; VIRUS CARCINOGENESIS; WART VIRUS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY;

EID: 77951498823     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328338475c     Document Type: Review

References (30)

1. Rischin D. Oropharyngeal cancer, human papilloma virus, and clinical trials. J Clin Oncol 2010; 28:1-3.
2. Egloff AM, Grandis JR. Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors. J Oncol 2009; 2009:896407.
3. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008; 83:489-501.
4. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17 346 patients. Radiother Oncol 2009; 92:4-14.
5. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
6. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-28.
7. Licitra L, Locati LD, Bossi P. Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. Ann Oncol 2008; 19 (Suppl 7):vii200-vii203.
8. Zhang N, Erjala K, Kulmala J, et al. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol 2009; 92:388-392.
9. Langer CJ, Lee JW, Patel UA, et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; 30 May to 3 June 2008. p. 317s.
10. Wanebo HJ, Ghebremichael M, Burtness B, et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). 43rd Annual ASCO Meeting. Chicago, IL; 1-5 June 2007. p. 302s.
11. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol 2007; 5:79-81.
12. Kruser TJ, Armstrong EA, Ghia AJ, et al. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 2008; 72:534-542.
13. Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in pa tients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010; 21:342-347.
14. Ang KK. Multidisciplinary management of locally advanced SCCHN: optimiz ing treatment outcomes. Oncologist 2008; 13:899-910.
15. Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C.
16. Head Neck. 2009, 31., 1393-1422.
17. A detailed review of HPV-related HNSCC and has addressed epidemiology, viral detection, pathological diagnosis, radiation therapy, chemoradiation therapy and future clinical trials in HPV-associated HNSCC.
18. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1992-1998.
19. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a pro spective clinical trial. J Natl Cancer Inst 2008; 100:261-269.
20. Kumar B, Cordell KG, Lee JS, etal. EGFR, p16, HPV titer, Bcl-xLand p53,sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26:3128-3137.
21. Klein JD, Grandis JR. The molecular pathogenesis of head and neck cancer. Cancer Biol Ther 2010. [Epub ahead of print]
22. Mineta H, Miura K, Ogino T, et al. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 2000; 83:775-781.
23. Onesto C, Hannoun-Levi JM, Chamorey E, et al. Vascular endothelial growth factor-Aand poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance. Br J Cancer 2006; 94:1516-1523.
24. Caponigro F, Formato R, Caraglia M, et al. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 2005; 17:212-217.
25. Tae K, El-Naggar AK, Yoo E, et al. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res 2000; 6:2821-2828.
26. Bozec A, Formento P, Lassalle S, et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 2007; 97:65-72.
27. Bozec A, Sudaka A, Fischel JL, et al. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008; 99:93-99.
28. Bozec A, Sudaka A, Toussan N, et al. Combination of sunitinib, cetuximaband irradiation in an orthotopic head and neck cancer model. Ann Oncol 2009; 20:1703-1707.
29. Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res 2009; 315:572-582.
30. Harrington KJ, El-Hariry IA, Holford CS, et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1100-1107.